Join 60 Degrees Pharmaceuticals' Live Investor Webinar: Advancing Tafenoquine for Babesiosis While Expanding ARAKODA(R) Commercialization
Key Highlights
- ➤Babesiosis study reached 24-patient interim-analysis enrollment threshold
- ➤Three relapsing-babesiosis patients were cured after tafenoquine treatment
- ➤Interim babesiosis data readout planned by October 6, 2026
- ➤Up to $245 million potential peak annual U.S. babesiosis sales estimated
- ➤ARAKODA expansion adds inside sales, digital marketing, GoodRx, and Runway Health access
Expert Statements
Geoff Dow, Chairman and CEO of 60 Degrees Pharmaceuticals
“The Company has also reached the minimum 24-patient enrollment required for an interim analysis of its randomized, double-blind, placebo-controlled study in hospitalized babesiosis patients, with an interim data readout planned by October 6, 2026.”
ORLANDO, FL / ACCESS Newswire / November 4, 2026 / RedChip Companies will host an investor webinar on Tuesday, November 10, 2026, at 4:15 p.m. ET with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP).
The exclusive event will feature Geoff Dow, Chairman and CEO, who will provide an overview of 60 Degrees Pharmaceuticals' strategy to develop and commercialize therapies for vector-borne diseases. The presentation will focus on the Company's FDA-approved antimalarial ARAKODA(®) (tafenoquine), its commercial expansion initiatives, and the advancement of tafenoquine for babesiosis, a tick-borne infection for which there is currently no FDA-approved treatment specifically for the disease.
Get started
Create a free account to read the full story.